Sol-Gel Technologies (SLGL) vs Zentalis Pharmaceuticals (ZNTL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Sol-Gel Technologies (SLGL) has outperformed Zentalis Pharmaceuticals (ZNTL) over the past year, gaining 78.9% versus a gain of 53.0%. Over five years, SLGL leads with a -24.6% price change compared with -96.6% for ZNTL. Zentalis Pharmaceuticals is the larger company by market cap ($259.0 million vs $235.0 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | SLGL | ZNTL |
|---|---|---|
| Share price | $71.77 | $2.64 |
| Market cap | $234.97M | $259.04M |
| 1-day change | +2.03% | +5.18% |
| YTD return | +66.92% | +85.93% |
| 1-year return | +78.89% | +53.05% |
| 5-year return | -24.57% | -96.65% |
| EPS (TTM) | $-5.79 | $-2.07 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $97.97 | $6.95 |
| 52-week low | $28.81 | $1.21 |
| Distance from 52-week high | -26.74% | -62.01% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +112.48% | +177.65% |
| Average volume | 55.55K | 1.21M |
| Shares outstanding | 3.27M | 98.12M |
| Employees | 28 | 106 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SLGL has outperformed ZNTL by 25.8 percentage points over the past year.
About Sol-Gel Technologies
SLGL stock →Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel, China, Switzerland, Canada, the United States and internationally. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea.
Health Care · Biotechnology: Pharmaceutical Preparations · 28 employees
About Zentalis Pharmaceuticals
ZNTL stock →Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. It develops azenosertib, which is in a Phase 3 clinical trial for the treatment of ovarian cancer and other tumor types.
Health Care · Biotechnology: Pharmaceutical Preparations · 106 employees
SLGL vs ZNTL FAQ
Which is bigger, Sol-Gel Technologies or Zentalis Pharmaceuticals?
Zentalis Pharmaceuticals (ZNTL) is larger, with a market capitalization of $259.04M compared with $234.97M for Sol-Gel Technologies (SLGL).
Which stock has performed better over the past year, SLGL or ZNTL?
SLGL returned +78.89% over the past 12 months, compared with +53.05% for ZNTL (price return, excluding dividends). Past performance does not predict future results.
Are Sol-Gel Technologies and Zentalis Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.